Interaction Checker

Avanafil etkileşimleri

PDE5 inhibitörü sınıfından Avanafil (Stendra) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 162 belgelenmiş etkileşim var: 45 majör, 117 orta, 0 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Avanafil nasıl görünür

6 sürümün tümü
Avanafil 100 mg tablet: sarı, oval, 9 mm, üzerinde 100mg baskısı var.
100mg
100 mg · sarı · oval · 9 mm
Metuchen
Avanafil 200 mg tablet: sarı, oval, 12 mm, üzerinde 200mg baskısı var.
200mg
200 mg · sarı · oval · 12 mm
Metuchen
Avanafil 50 mg tablet: sarı, oval, 7 mm, üzerinde 50mg baskısı var.
50mg
50 mg · sarı · oval · 7 mm
Metuchen
Avanafil 50 mg tablet: beyaz, oval, 7 mm, bir yüzünde A41, diğer yüzünde H baskısı var.
A41 / H
50 mg · beyaz · oval · 7 mm
Camber

Çizimler, FDA etiketlerindeki ürün bilgilerinden oluşturulmuştur: renk, şekil, boyut ve baskı. 2 firmaya ait 6 belgelenmiş sürüm.

Etikete göre etkileşimler

Majör etkileşimler (45)

  • AmiodaronantiaritmikMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • AprepitantCYP3A4 inhibitörüMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • AtazanavirantiretroviralMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • DarunavirantiretroviralMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • DronedaronantiaritmikMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Elvitegravir, kobisistat, emtrisitabin ve tenofovirantiretroviralMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Eritromisinmakrolid antibiyotikMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • EverolimusimmünosüpresanMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • FosamprenavirantiretroviralMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • FosaprepitantCYP3A4 inhibitörüMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • İtrakonazolazol antifungalMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • İvakaftorCYP3A4 inhibitörüMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • İzosorbid dinitratnitratMajör

    • Administration of avanafil tablet to patients using any form of organic nitrate is contraindicated ( 4.1 ) (Avanafil etiketi, Kontrendikasyonlar)

  • İzosorbid dinitrat ve hidralazinnitratMajör

    • Administration of avanafil tablet to patients using any form of organic nitrate is contraindicated ( 4.1 ) (Avanafil etiketi, Kontrendikasyonlar)

  • İzosorbid mononitratnitratMajör

    • Administration of avanafil tablet to patients using any form of organic nitrate is contraindicated ( 4.1 ) (Avanafil etiketi, Kontrendikasyonlar)

  • Ketokonazolazol antifungalMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Klaritromisinmakrolid antibiyotikMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Lopinavir ve ritonavirantiretroviralMajör

    Do not use avanafil in patients taking ritonavir. (Avanafil etiketi, İlaç etkileşimleri)

  • MifepristonCYP3A4 inhibitörüMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • NefazodonantidepresanMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Nirmatrelvir ve ritonavirantiviralMajör

    Do not use avanafil in patients taking ritonavir. (Avanafil etiketi, İlaç etkileşimleri)

  • NitrogliserinnitratMajör

    • Administration of avanafil tablet to patients using any form of organic nitrate is contraindicated ( 4.1 ) (Avanafil etiketi, Kontrendikasyonlar)

  • PalbosiklibCYP3A4 inhibitörüMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • PerampanelantikonvülsanMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • RanolazinQT aralığını uzatan ilaçMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • RiosiguatvazodilatörMajör

    • Administration with guanylate cyclase (GC) stimulators such as riociguat and vericiguat ( 4.3 ) (Avanafil etiketi, Kontrendikasyonlar)

  • RitonavirantiretroviralMajör

    Do not use avanafil in patients taking ritonavir. (Avanafil etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Suvoreksantsedatif-hipnotikMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Tikagrelorantitrombosit ilaçMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

  • VerisiguatvazodilatörMajör

    • Administration with guanylate cyclase (GC) stimulators such as riociguat and vericiguat ( 4.3 ) (Avanafil etiketi, Kontrendikasyonlar)

  • Vorikonazolazol antifungalMajör

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

Orta düzey etkileşimler (117)

  • Alfuzosinalfa blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • AliskirenantihipertansifOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • AlkolAlkolOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Alprostadilprostaglandin analoğuOrta

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Avanafil etiketi, Uyarılar ve önlemler)

  • Amiloridpotasyum tutucu diüretikOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Amlodipindihidropiridin kalsiyum kanal blokeriOrta

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (Avanafil etiketi, İlaç etkileşimleri)

  • Amlodipin ve atorvastatindihidropiridin kalsiyum kanal blokeriOrta

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (Avanafil etiketi, İlaç etkileşimleri)

  • Amlodipin ve benazeprildihidropiridin kalsiyum kanal blokeriOrta

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (Avanafil etiketi, İlaç etkileşimleri)

  • Amlodipin ve olmesartandihidropiridin kalsiyum kanal blokeriOrta

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (Avanafil etiketi, İlaç etkileşimleri)

  • Amlodipin ve valsartandihidropiridin kalsiyum kanal blokeriOrta

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (Avanafil etiketi, İlaç etkileşimleri)

  • Asebutololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Atenololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Atenolol ve klortalidonbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Azilsartananjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • BenazeprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Benazepril ve hidroklorotiyazidACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Betaksololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Biktegravir, emtrisitabin ve tenofovir alafenamidantiretroviralOrta

    PDE-5 inhibitors for erectile dysfunction (ED): Refer to the prescribing information of PDE-5 inhibitors for dose recommendations. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

  • Bisoprololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Bisoprolol ve hidroklorotiyazidbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Bizmut subsitrat, metronidazol ve tetrasiklinantibiyotikOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • DisülfiramCYP2C9 inhibitörüOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • Doksazosinalfa blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Dutasterid ve tamsulosin5-alfa redüktaz inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • EnalaprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Enalapril ve hidroklorotiyazidACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • EnalaprilatACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Eplerenonaldosteron antagonistiOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Epoprostenolprostaglandin analoğuOrta

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Avanafil etiketi, Uyarılar ve önlemler)

  • Etakrinik asitkıvrım (loop) diüretiğiOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • EtravirinantiretroviralOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • Felodipindihidropiridin kalsiyum kanal blokeriOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • FenilefrindekonjestanOrta

    Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (Fenilefrin etiketi, İlaç etkileşimleri)

  • Fenoksibenzaminalfa blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Fentolaminalfa blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • FluorourasilantimetabolitOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • FluvastatinstatinOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • FosinoprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Fosinopril ve hidroklorotiyazidACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Furosemidkıvrım (loop) diüretiğiOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • GreyfurtYiyecek ve içecekOrta

    Although specific interactions have not been studied, other CYP3A4 inhibitors, including grapefruit juice are likely to increase avanafil exposure. (Avanafil etiketi, İlaç etkileşimleri)

  • Guanfasinalfa adrenerjik agonistOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • HidralazinvazodilatörOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Hidroklorotiyazidtiyazid diüretikOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • İndapamidtiyazid diüretikOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • İrbesartananjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • İsradipindihidropiridin kalsiyum kanal blokeriOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Kandesartananjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Kannabidiol (reçeteli)antikonvülsanOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • KapesitabinantimetabolitOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • KaptoprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Karvedilolbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • KinaprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Kinapril ve hidroklorotiyazidACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Klonidinalfa adrenerjik agonistOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Klorotiyazidtiyazid diüretikOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Klortalidontiyazid diüretikOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Labetalolbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • LisinoprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Lisinopril ve hidroklorotiyazidACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Lofeksidinalfa adrenerjik agonistOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Losartananjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • MekamilaminantihipertansifOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • MetildopaantihipertansifOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Metolazontiyazid diüretikOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Metoprololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Metoprolol ve hidroklorotiyazidbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • MetronidazolantibiyotikOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • Mikonazolazol antifungalOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • MinoksidilvazodilatörOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • MoeksiprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Nadololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Nebivololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Nifedipindihidropiridin kalsiyum kanal blokeriOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Nikardipindihidropiridin kalsiyum kanal blokeriOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Nimodipindihidropiridin kalsiyum kanal blokeriOrta

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Nimodipin etiketi, İlaç etkileşimleri)

  • Nisoldipindihidropiridin kalsiyum kanal blokeriOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • NitisinonCYP2C9 inhibitörüOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • NitroprussidvazodilatörOrta

    In vitro studies with human platelets indicate that avanafil potentiates the anti-aggregatory effect of sodium nitroprusside (a nitric oxide [NO] donor). (Avanafil etiketi, Uyarılar ve önlemler)

  • Olmesartananjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (Avanafil etiketi, İlaç etkileşimleri)

  • PapaverinvazodilatörOrta

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Avanafil etiketi, Uyarılar ve önlemler)

  • PerindoprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Pindololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Prazosinalfa blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Propranololbeta blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • RamiprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • RifapentinantibiyotikOrta

    …Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl… (Rifapentin etiketi, İlaç etkileşimleri)

  • Sakubitril ve valsartananjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • SapropterinOrta

    Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors) : Potential for vasorelaxation; monitor blood pressure. (Sapropterin etiketi, İlaç etkileşimleri)

  • SepiapterinOrta

    Drugs Affecting Nitric Oxide-Mediated Vasorelaxation : Potential for vasorelaxation; monitor blood pressure (e.g., PDE-5 inhibitors). (Sepiapterin etiketi, İlaç etkileşimleri)

  • SildenafilPDE5 inhibitörüOrta

    Prolonged Erection Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors. (Avanafil etiketi, Uyarılar ve önlemler)

  • Silodosinalfa blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Spironolaktonaldosteron antagonistiOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Sülfametoksazol ve trimetoprimsülfonamidOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • TadalafilPDE5 inhibitörüOrta

    Prolonged Erection Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors. (Avanafil etiketi, Uyarılar ve önlemler)

  • Tamsulosinalfa blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Telmisartananjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Telmisartan ve amlodipinanjiyotensin II reseptör blokeri (ARB)Orta

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (Avanafil etiketi, İlaç etkileşimleri)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Terazosinalfa blokerOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Tizanidinkas gevşeticiOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Torasemidkıvrım (loop) diüretiğiOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • TrandolaprilACE inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Treprostinilprostaglandin analoğuOrta

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (Avanafil etiketi, Uyarılar ve önlemler)

  • Triamterenpotasyum tutucu diüretikOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • TrimetoprimantibiyotikOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

  • Valsartananjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • VardenafilPDE5 inhibitörüOrta

    Prolonged Erection Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors. (Avanafil etiketi, Uyarılar ve önlemler)

  • Zafirlukastlökotrien reseptör antagonistiOrta

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Avanafil ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.